- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: AVT04: An Ustekinumab Biosimilar ; volume:44 ; number:10 ; day:28 ; month:9 ; year:2024 ; pages:799 ; date:10.2024
Clinical drug investigation ; 44, Heft 10 (28.9.2024), 799, 10.2024
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-024-01393-9
- URN
-
urn:nbn:de:101:1-2501122118092.034885938120
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab